Previous work has identified elevated tumor aneuploidy as a marker of low overall survival and can be used as a biomarker for clinical outcomes of immunotherapy (12), and we found that the copy number value of METTL1 altered samples had higher aneuploidy score (Figure 6F). Here, METTL1 is linked to neoplasm.